HUTCHMED (China) Ltd (LSE:HCM) - Share price


Stock Report

HUTCHMED (China) Ltd HCM

Last Price
GBX211.50

Day Change
-7.50|-3.42%

As of 29/06/2022
18:02:49 BST | GBX
Minimum 15 Minutes Delay.

Last Close219.00p
Day Range208.00 - 215.50
Mkt Cap1.89Bil
52-Wk Range137.80 - 656.00
Yield %-
ISINKYG4672N1198
Volume118,874
P/E15.36
P/S4.71
P/CF-8.20

Share Price

Total Returns 28/06/2022

 Chg (%)  
More ...
HUTCHMED (China) Ltd46.19 
FTSE 100 TR GBP-3.23
 
Financials
201920202021
More ...
Income Statement
Turnover204.89227.98356.13
Operating Profit-146.39-196.67-328.32
Net Profit-103.68-115.52-167.04
Reported EPS-0.16-0.18-0.25
Balance Sheet
Current Assets317.02530.741,212.08
Non Current Assets148.10193.38160.59
Total Assets465.12724.121,372.66
Current Liabilities113.10158.40311.66
Total Liabilities152.22205.17333.15
Total Equity312.90518.951,039.51
Cash Flow
Operating Cash Flow-80.91-62.07-204.22
Net Change in Cash36.62108.93139.49
Director Dealings
TradedActionNotifierPriceAmountValue
More ...
20/04/2022Transfer inMr. Graeme Allan Jack0.0011,9850.00
20/04/2022Transfer inMr. Dan Eldar0.0011,9850.00
20/04/2022Transfer inMs. Edith Shih0.0011,9850.00
20/04/2022Transfer inMr. Paul Rutherford Carter0.0010,1850.00

Company Profile

HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Its reportable segments include the innovation platform and commercial platform. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The commercial platform includes a prescription drugs business and a consumer health business for over-the-counter drugs.

Sector

Drug Manufacturers - Specialty & Generic

Index

FTSE AIM 100 , FTSE AIM All-Share

Next Event 28/07/2022

Half-Yearly Results
Ratios
Comp
More ...
PER (E)0.00
Div Yld (E)0.00
PEG (E)0.00
ROCE-20.28
Op Mrgn-0.92
EPS Grwth0.00
Dividends
PreviousLatest
More ...
Record Datet.b.c.t.b.c.
Ex-Divt.b.c.t.b.c.
Paidt.b.c.t.b.c.
Amnt0.000.00
Directors
More ...
Non-Executive DirectorMr. Graeme Allan Jack
Non-Executive DirectorMr. Dan Eldar
Non-Executive Director, Company SecretaryMs. Edith Shih
Non-Executive Director, Senior Independent DirectorMr. Paul Rutherford Carter
Executive Director, ChairmanMr. Chi Keung Simon To
Executive Director, Chief Financial OfficerMr. Johnny Cheng Chig FUNG
Non-Executive DirectorDr. Karen Jean Ferrante
Executive Director, Chief Executive OfficerDr. Weiguo Su
Non-Executive DirectorProfessor Shu Kam Tony Mok
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2022 Morningstar. All rights reserved.